Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report) and Revance Therapeutics (RVNC – Research Report).
Regeneron (REGN)
Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Regeneron today and set a price target of $873.00. The company’s shares closed last Tuesday at $725.70.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $841.45, which is a 15.1% upside from current levels. In a report issued on January 20, J.P. Morgan also upgraded the stock to Buy with a $850.00 price target.
See the top stocks recommended by analysts >>
Revance Therapeutics (RVNC)
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Revance Therapeutics, with a price target of $26.00. The company’s shares closed last Tuesday at $33.27, close to its 52-week high of $34.22.
According to TipRanks.com, Flynn is a 4-star analyst with an average return of
Currently, the analyst consensus on Revance Therapeutics is a Moderate Buy with an average price target of $31.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Regeneron upgraded to Overweight from Neutral at JPMorgan
- Piper ‘at a loss’ to explain Regeneron Q4 miss for Eylea
- Regeneron sees about $1.5B in Q4 U.S. net product sales of Eylea
- FDA Dermatologic & Ophthalmic Drugs Advisory Committee Virtual Meeting
